Compass Pathways (CMPS) to Release Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Compass Pathways to post earnings of ($0.39) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 2:00 AM ET.

Compass Pathways Trading Up 10.7%

Shares of CMPS stock opened at $8.45 on Thursday. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average price is $6.80 and its 200-day moving average price is $5.91. Compass Pathways has a twelve month low of $2.25 and a twelve month high of $8.90. The stock has a market cap of $811.37 million, a price-to-earnings ratio of -3.11 and a beta of 1.92.

Compass Pathways News Summary

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Positive Phase III topline: COMP360 met its primary endpoint in a late‑stage trial (statistically significant symptom reduction, rapid onset and durability through later weeks), strengthening the drug’s clinical and regulatory outlook and lifting sector sentiment. Read More.
• Positive Sentiment: Analyst support: Analysts have an average rating of “Moderate Buy,” which can sustain inflows and provide selling-pressure resistance after the clinical win. Read More.
• Neutral Sentiment: Options and trading flows: Unusually large call option volume suggests short-term speculative/bullish positioning; this can amplify intraday moves but doesn’t change fundamentals.
• Neutral Sentiment: Confusing short‑interest report: recent data showing zero shares and NaN changes appears unreliable and offers no clear signal to investors; ignore until clarified by a trustworthy data release.
• Negative Sentiment: Equity raise and dilution risk: Compass launched a proposed $150M public offering to fund development and commercialization. The raise — and reporting that the offering price is deeply discounted to recent levels — prompted pre‑market weakness and creates near‑term dilution that can cap upside until proceeds are deployed. Read More.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on CMPS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a report on Wednesday, January 21st. Royal Bank Of Canada upped their price target on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research note on Wednesday. Canaccord Genuity Group increased their price target on Compass Pathways from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Morgan Stanley boosted their price objective on shares of Compass Pathways from $11.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and a consensus target price of $17.56.

Hedge Funds Weigh In On Compass Pathways

Several institutional investors have recently bought and sold shares of CMPS. RTW Investments LP lifted its position in shares of Compass Pathways by 0.6% during the fourth quarter. RTW Investments LP now owns 8,757,390 shares of the company’s stock worth $60,426,000 after purchasing an additional 50,000 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares in the last quarter. Millennium Management LLC boosted its position in Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock valued at $15,562,000 after buying an additional 774,090 shares during the period. Toronto Dominion Bank grew its stake in shares of Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock worth $17,447,000 after acquiring an additional 1,529,013 shares in the last quarter. Finally, ARK Investment Management LLC increased its position in shares of Compass Pathways by 1.6% during the fourth quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after acquiring an additional 34,894 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.